Pooled Analysis of 45 Real-World, Investigator-Led Trials Explores Efficacy and Safety of an Antiseizure Medication in Focal and Generalized Epilepsy

Join Dr Michael G. Chez as he presents the PERMIT extension study, a pooled analysis of data from 2 large, clinical practice studies conducted to assess the effectiveness, safety, and tolerability of FYCOMPA® (perampanel) in everyday clinical practice for patients with focal and generalized seizures. He also reviews the study of the effects of FYCOMPA on cognition in adolescents.

View Transcript
Share

INDICATION
FYCOMPA® (perampanel) is indicated in patients with epilepsy aged 4 years and older for partial-onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy for patients aged 12 years and older for primary generalized tonic-clonic (PGTC) seizures.

Please see additional Important Safety Information throughout and full US Prescribing Information, including Boxed WARNING.

Faculty

Michael G. Chez, MD, FAAN, FAES
Pediatric Epileptologist
Regional Director, Pediatric Epilepsy Research
Sutter Health
Roseville and Sacramento, CA
Professor, California State University
Elk Grove, CA